Hitchhiking cancer vaccine makes progress in the clinic
Elicio Therapeutics is testing a pancreatic cancer vaccine using technology first developed at MIT in clinical trials, with promising Phase 1 results.
Source: mit.edu
Christopher Haqq News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Christopher Haqq. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Christopher Haqq Today - Breaking & Trending Today
Cancer Vaccine Likely 'Several Years' Away From Wide Availability
ELI-002, a vaccine for the postsurgical treatment of KRAS-mutated pancreatic and colorectal cancers, is showing promising early study results — but potential commercial availability of the drug is likely several years away as one researcher tells CURE®.
Source: curetoday.com
Nature Medicine Publishes Two Studies Highlighting Signatera's Clinical Utility in Patients with Gastrointestinal Malignancies -January 25, 2024 at 07:04 am EST
AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors PANDA study shows...
Source: marketscreener.com
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker reduction, with strong T cell responses...
Source: marketscreener.com
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
BOSTON, Jan. 16, 2024 -- Elicio Therapeutics, Inc. , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert...
Source: marketscreener.com